Legal Proceedings
−Removed: We are not a party to any material legal proceedings at this time.
−Removed: From time to time, we may be subject to various legal proceedings and claims that arise in the ordinary course of our business activities.
−Removed: Although the results of litigation and claims cannot be predicted with certainty, we do not believe we are party to any claim or litigation the outcome of which, if determined adversely to us, would individually or in the aggregate be reasonably expected to have a material adverse effect on our results of operations or financial condition.
−Removed: Regardless of the outcome, litigation can have an adverse effect on us because of defense and settlement costs, diversion of management resources and other factors.
+Added: On October 9, 2025 and October 22, 2025, two substantially similar putative securities class action complaints were filed in the U.S.
+Added: District Court for the Southern District of California, naming aTyr Pharma, Inc.
+Added: and our Chief Executive Officer, Sanjay Shukla.
+Added: The complaints allege certain violations of the U.S.
+Added: federal securities laws and seek unspecific damages.
+Added: We believe we have meritorious defenses and intend to vigorously defend the Company in this matter.
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.